News Related to Primary Liver Cancer

Related coverage linked through entity extraction aliases.

Lantern Pharma Announces FDA Orphan Drug Designation for LP-284 and USPTO Patent Allowance for LP-184

Jul 24, 2026

Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.

Meta-Analysis Finds Only Six Side Effects Causally Linked to Statins

Mar 09, 2026

A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.